FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer…

Continue Reading FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

Breaking the “Undruggable” Barrier: FOG-001 Earns FDA Fast Track for Rare Soft-Tissue Cancer

Parabilis Medicines has achieved a significant milestone in cancer drug development, receiving FDA Fast Track designation for FOG-001, a groundbreaking first-in-class therapy targeting desmoid tumors. As reported by Drugs.com, this…

Continue Reading Breaking the “Undruggable” Barrier: FOG-001 Earns FDA Fast Track for Rare Soft-Tissue Cancer

EMA Recommends Orphan Drug Status for BioInvent’s BI-1808 in Cutaneous T-Cell Lymphoma

As reported by PharmaBiz, the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion supporting Orphan Drug Designation (ODD) for BioInvent’s BI-1808, an investigational anti-TNFR2…

Continue Reading EMA Recommends Orphan Drug Status for BioInvent’s BI-1808 in Cutaneous T-Cell Lymphoma

“The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma

Editor's Note: Patient Worthy is proud to share this story from our friends at Elephants & Tea. To see the story in its original format, please click here. “Well, good…

Continue Reading “The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma

Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Biomarker analysis plays a pivotal role in cancer care and research, guiding the development of targeted therapies and enabling personalized treatment plans. While next-generation sequencing (NGS) has revolutionized the ability…

Continue Reading Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Datroway Shows Survival Benefit in Late-Stage Trial for Triple-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo have announced promising Phase 3 trial results for Datroway, their investigational antibody-drug conjugate (ADC) targeting triple-negative breast cancer (TNBC). The trial demonstrated that Datroway significantly slowed…

Continue Reading Datroway Shows Survival Benefit in Late-Stage Trial for Triple-Negative Breast Cancer

Early Research on Two Tough Cancers

Pancreatic cancer took Alex Trebek, Michael Landon, Ruth Bader Ginsburg, Luciano Pavarotti, Steve Jobs,  Patrick Swayze, and my dear friend Amy. Glioblastoma (GBM) took Senators John McCain and Ted Kennedy,…

Continue Reading Early Research on Two Tough Cancers

The Unspoken Guilt of Living

Editor's Note: Patient Worthy is honored to share this story from our friends at Elephants & Tea. To see the article in its original form, please click here. Original author…

Continue Reading The Unspoken Guilt of Living